Sinphar Pharmaceutical Co (TPE:1734) Beneish M-Score: -2.58 (As of Jun. 26, 2026)


TPE:1734 Sinphar Pharmaceutical Co Ltd TPE:1734
81 GF Score
Price NT$32.00
GF Value NT$33.13
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Sinphar Pharmaceutical Co Beneish M-Score?

Sinphar Pharmaceutical Co TPE:1734 -1.08% 81 Beneish M-Score is -2.58 as of Jun. 26, 2026. GuruFocus rates TPE:1734 with a GF Score™ of 81/100 and a GF Value™ of NT$33.13 (Fairly Valued). The stock has 1 warning sign investors should review. Among 831 Biotechnology companies, Sinphar Pharmaceutical Co ranks better than 59.69% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.58 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sinphar Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

TPE:1734' s Beneish M-Score Range Over the Past 10 Years
Min: -2.95   Med: -2.59   Max: -2.19
Current: -2.58

During the past 13 years, the highest Beneish M-Score of Sinphar Pharmaceutical Co was -2.19. The lowest was -2.95. And the median was -2.59.


Sinphar Pharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sinphar Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinphar Pharmaceutical Co Beneish M-Score Chart

Sinphar Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.36 -2.59 -2.19 -2.70 -2.58

Sinphar Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.70 -2.71 -2.69 -2.45 -2.58

TPE:1734 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Sinphar Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinphar Pharmaceutical Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinphar Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sinphar Pharmaceutical Co's Beneish M-Score falls into.


TPE:1734
81GF Score
Sinphar Pharmaceutical Co Ltd TPE:1734
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinphar Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sinphar Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0393+0.528 * 0.9086+0.404 * 0.9817+0.892 * 1.07+0.115 * 1.0011
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0561+4.679 * -0.035578-0.327 * 0.898
=-2.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$714 Mil.
Revenue was 880.023 + 872.734 + 812.977 + 805.587 = NT$3,371 Mil.
Gross Profit was 382.463 + 382.492 + 346.473 + 345.463 = NT$1,457 Mil.
Total Current Assets was NT$2,529 Mil.
Total Assets was NT$6,153 Mil.
Property, Plant and Equipment(Net PPE) was NT$3,280 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$254 Mil.
Selling, General, & Admin. Expense(SGA) was NT$895 Mil.
Total Current Liabilities was NT$1,011 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1,273 Mil.
Net Income was 101.951 + 83.352 + 68.061 + 112.387 = NT$366 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0 Mil.
Cash Flow from Operations was 200.629 + 203.238 + 116.836 + 63.959 = NT$585 Mil.
Total Receivables was NT$642 Mil.
Revenue was 854.389 + 749.518 + 769.325 + 777.396 = NT$3,151 Mil.
Gross Profit was 347.685 + 272.112 + 298.696 + 318.523 = NT$1,237 Mil.
Total Current Assets was NT$2,624 Mil.
Total Assets was NT$6,298 Mil.
Property, Plant and Equipment(Net PPE) was NT$3,316 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$257 Mil.
Selling, General, & Admin. Expense(SGA) was NT$792 Mil.
Total Current Liabilities was NT$1,423 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1,181 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(713.858 / 3371.321) / (641.9 / 3150.628)
=0.211744 / 0.203737
=1.0393

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1237.016 / 3150.628) / (1456.891 / 3371.321)
=0.392625 / 0.432142
=0.9086

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2529.232 + 3280.385) / 6153.05) / (1 - (2624.355 + 3315.81) / 6298.255)
=0.055815 / 0.056855
=0.9817

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3371.321 / 3150.628
=1.07

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(257.37 / (257.37 + 3315.81)) / (254.331 / (254.331 + 3280.385))
=0.072028 / 0.071952
=1.0011

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(894.665 / 3371.321) / (791.648 / 3150.628)
=0.265375 / 0.251267
=1.0561

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1273.067 + 1011.481) / 6153.05) / ((1181.205 + 1422.809) / 6298.255)
=0.371287 / 0.41345
=0.898

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(365.751 - 0 - 584.662) / 6153.05
=-0.035578

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sinphar Pharmaceutical Co has a M-score of -2.58 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.58 mean?
Sinphar Pharmaceutical Co (TPE:1734) has a Beneish M-Score of -2.58 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sinphar Pharmaceutical Co and its competitors. According to the industry distribution chart, Sinphar Pharmaceutical Co ranks #335 out of 831 companies in the Biotechnology industry, placing it in the top 40.3%.
Is Sinphar Pharmaceutical Co's Beneish M-Score too high?
Sinphar Pharmaceutical Co's current Beneish M-Score is -2.58. Based on the distribution chart, Sinphar Pharmaceutical Co ranks #335 out of 831 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinphar Pharmaceutical Co ranks #335 out of 831 companies for Beneish M-Score. This puts Sinphar Pharmaceutical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sinphar Pharmaceutical Co and its competitors. Sinphar Pharmaceutical Co's current Beneish M-Score is -2.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.13, compared to a current price of NT$32.00 — trading 3.4% below its estimated fair value. The current Beneish M-Score is -2.58. Sinphar Pharmaceutical Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current Beneish M-Score is -2.58 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?

Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$32.00 is trading 3.4% below its estimated GF Value™ of NT$33.13. GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TPE:1734:

  • Beneish M-Score: -2.58
  • GF Value™: NT$33.13 vs. price of NT$32.00 (3.4% below fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sinphar Pharmaceutical Co Business Description

Address No.84, Zhongshan Road, Dongshan Township, Zhongshan Village, Yilan, TWN, 269
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
81GF Score

Get the complete analysis for TPE:1734

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.00
Price
NT$33.13
GF Value